- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Biologics Evaluation and Research
This guidance provides to you, medical device manufacturers of communicable disease tests, information about performing studies to support modifying the indication for use to include testing of cadaveric blood pecimens to screen donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). This guidance makes recommendations about:
• Sensitivity and specificity studies • Reproducibility studies • Number of test kit lots to include in studies
• Plasma dilution issues
• Information about specimen collection times to be included
This document contains information which has been provided in Center for Biologic Evaluation and Research’s (CBER’s) letters to manufacturers of communicable disease tests. We, FDA, continue to encourage Manufacturers of communicable disease tests to evaluate these tests for cadaveric HCT/P donor use and seek such labeling.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: 2005D-0056.